<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02062489</url>
  </required_header>
  <id_info>
    <org_study_id>BCCT2014001</org_study_id>
    <nct_id>NCT02062489</nct_id>
  </id_info>
  <brief_title>Evaluation of Tamoxifen's Efficacy for ER/PR Negative,ER-beta Positive Operable Breast Cancer Patients</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study is a multicentre, randomized,double-blind, prospective clinical trial
      stratified patients by the HER2 status of their cancer (negative or positive) which is
      sponsored by the researchers. The trial is designed to evaluate the effectiveness of
      tamoxifen as adjuvant therapy for ER(ER-α)/PR negative, ER-β positive operable breast cancer
      patients. 688 female ER(ER-α)/PR negative, ER-β(wild type ER-β1) positive operable breast
      cancer patients who had undergone neoadjuvant chemotherapy or directly modified radical
      mastectomy or breast-conserving surgery were randomly (1:1) enrolled to receive tamoxifen (20
      mg per day) or placebo (2# per day) within 6 weeks after postoperative chemotherapy and/or
      radiation therapy if needed (according to 2013 NCCN breast cancer guideline). If the breast
      tumor's HER2 is positive, the patient can receive targeted therapy (Herceptin) combined with
      tamoxifen or placebo. The follow-up time will be eight years. The aim of this trial is to
      evaluate the effectiveness of tamoxifen as adjuvant therapy for ER(ER-α)/PR negative, ER-β
      positive operable breast cancer patients by comparing the DFS and OS between tamoxifen group
      and placebo group and to determine whether the percentage of positive ER-β expression is
      associated with the response to the hormone therapy in breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival of patients</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of adverse reactions</measure>
    <time_frame>within 5 years when patients is undergoing tamoxifen or placebo treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>within 10 years after diagnosis</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">688</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Tamoxifen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20mg(2#)/day, PO, daily, five years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2#/day, PO, daily, five years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tamoxifen</intervention_name>
    <description>20 mg(2#)/day, PO, daily</description>
    <arm_group_label>Tamoxifen</arm_group_label>
    <other_name>Nolvadex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2#/day, PO, daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patients signed the written informed consent

          -  The patients present with operable unilateral invasive breast cancers without distant
             metastasis(stage I, II, and III)

          -  The breast tumor's positive ER/PR rate is &lt;1%, and positive ER-beta1 rate is ≥10% by
             IHC.

          -  The patients have no history of neoadjuvant hormone therapy.

          -  The patients have normal cardiac functions by echocardiography.

          -  The patients' ECOG scores are ≤0-2.

          -  Female patient who is ≥ 18yrs, and ≤ 65yrs.

          -  The patients are non-pregnant, and disposed to practice contraception during the whole
             trial.

          -  The patients underwent neoadjuvant chemotherapy plus surgery or directly modified
             radical mastectomy or breast-conserving surgery (plus sentinel lymph node biopsy or
             axillary lymph node dissection) after diagnosis of breast cancer.

          -  The patients underwent chemotherapy, radiation therapy or targeted therapy(herceptin)
             after surgery according to the 2013 NCCN guideline.

          -  The results of patients' blood tests are as follows:

        Hb≥90g/L; WBC≥4.0×109/L; Plt≥100×109/L; Neutrophils≥1.5×109/L; ALT and AST ≤ triple of
        normal upper limit; TBIL ≤ 1.5 times of normal upper limit; Creatinine ≤ 1.25 times of
        normal upper limit.

        Exclusion Criteria:

          -  The patients have other cancers at the same time or have the history of other cancers
             except controlled skin basal cell carcinoma or skin squamous cell carcinoma or
             carcinoma in situ of cervix uterus;

          -  The patients have active infections that were not suitable for chemotherapy;

          -  The patients have severe non-cancerous diseases.

          -  The patients have history of neoadjuvant hormone therapy.

          -  The patients have bilateral breast cancers or DCIS or metastatic breast cancers.

          -  The patients are undergoing current administration of anti-cancer therapies, or are
             attending other clinical trials.

          -  The patients are pregnant or lactational, or they refuse to practice contraception
             during the whole trial.

          -  The patients are in some special conditions that they can't understand the written
             informed consent, such as they are demented or hawkish.

          -  The patients have allergic history or contraindication of tamoxifen.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erwei Song, M.D.,Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Sun Yat-Sen Memerial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qiang Liu, MD.PhD.</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erwei Song, M.D., Ph. D.</last_name>
    <phone>86-20-81332576</phone>
    <email>songerwei02@yahoo.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Qiang Liu, M.D., Ph. D.</last_name>
    <phone>86-20-81332576</phone>
    <email>victorlq@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenbo Zheng</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuanghong Wu, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangdong Women and Children Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anqin Zhang</last_name>
      <phone>86-13925115929</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou Army General Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chenfang Zhang</last_name>
      <phone>86-13889908978</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoming Xie, M.D.,Ph.D.</last_name>
      <phone>86-13826109540</phone>
      <email>xiexm@sysucc.org.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwei Song, M.D.,Ph.D.</last_name>
      <email>songerwei02@yahoo.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Qiang Liu</last_name>
      <email>victorlq@hotmail.com.com</email>
    </contact_backup>
    <investigator>
      <last_name>Erwei Song, M.D.,Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangzhou Women and Children Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongmin Ma</last_name>
      <phone>86-13922723808</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinjiang Medical School Cancer Center</name>
      <address>
        <city>Xinjiang</city>
        <state>Xinjiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Binlin Ma, M.D.</last_name>
    </contact>
    <contact_backup>
      <last_name>Gang Sun, M.D.</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongjian Yang, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 12, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2014</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University</investigator_affiliation>
    <investigator_full_name>Erwei Song, M.D., Ph.D.</investigator_full_name>
    <investigator_title>Vice President of Sun Yat-Sen Memorial Hospital</investigator_title>
  </responsible_party>
  <keyword>breast cancer,</keyword>
  <keyword>tamoxifen,</keyword>
  <keyword>ER/PR negative, ER-beta positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

